Ad
Tuesday, 9 January 2018
U.S. pharma executives expect deals to pick up after tax overhaul
SAN FRANCISCO (Reuters) - The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment